This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Home
Products
Typhim Vi (Typhoid Polysaccharide Vaccine)®

TYPHIM Vi®

typhoid polysaccharide vaccine

Summary

TYPHIM Vi is indicated for active immunisation against typhoid fever caused by Salmonella enterica serovar typhi, S.typhi in adults and children 2 years of age or older.

Before you prescribe this vaccine please refer to the SmPC.

Usage

Provide active immunisation against typhoid fever caused by Salmonella Typhi in adults and children1
AgeInitial doseBooster / revaccinationDuration of protection
From 2 years of age11 dose of 0.5 millilitre1Revaccinate every 36 months depending on risk1Around 36 months1

The most common adverse reactions, in all age groups, were injection site pain. In adults from 18 years of age, myalgia and fatigue were the most frequently reported systemic reactions. In children and adolescents (from 2 to 17 years of age), myalgia and headache were the most frequently reported systemic reactions.

Most adverse reactions appeared within 3 days after vaccination. Most reactions resolved spontaneously within 1 to 3 days after onset. For a full list of adverse events please see product SMPC.

 
 
References
  1. UK Summary of Product Characteristics - Typhim

MAT-XU-2301128 (v4.0) Date of preparation: May 2025